Microbicide gel may offer protection against HIV

New research has found that the use of a vaginal gel in two separate studies showed effectiveness of protecting against the spread of HIV.

During the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial, two groups of scientists examined the effects of a microbicide gel on more than 880 women aged 18 to 40 years. Participants were sexually active and at high risk of contracting the disease.

Approximately 12 hours before they had sex, the women were asked to vaginally insert a dose of the gel, and use a second dose 12 hours after the intercourse. Regardless of the amount of sexual activity, participants were recommended not to use more than two doses within a 24-hour time frame.

The results of the trial showed that those who used the microbicide gel for the period of 12 to 18 months were were about 40 percent less likely to contract HIV.

"While we pause to mark this important milestone, we can't afford to idle," said Yasmin Halima, director of the Global Campaign for Microbicides. She added that "with the support of donors, governments, scientists and communities working together, the HIV-prevention field can accelerate efforts to halt the pandemic, focusing on the world's most vulnerable people. Today's news brings us one step closer to that brighter future."